User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8719

Interactions with Platform & by Email *

INTERACTIONS

1221

Unique # Participated *

PARTICIPANTS

262

Responses Validated *

VALIDATIONS

50

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Global Market Analysis.....II-1
Global Market Analysis by Disease Type.....II-1
1$100
   Neurodegenerative Drugs – The Next Big Thing in Healthcare.....II-2
Alzheimer’s and Parkinson’s Market.....II-2
Factors Affecting the Market.....II-2
Major Growth Drivers Ahead.....II-2
1$100
   Major Growth Inhibitors.....II-3
Rapid Growth of Aging Population.....II-3
Table 1: Global 65+ Age Group Population in Millions (includes corresponding Graph/Chart).....II-3
1$350
   Higher Alzheimer’s and Parkinson’s Prevalence.....II-4
Price Hikes and Government Caps.....II-4
Future Holds Promise!.....II-4
Research & Development.....II-4
1$100
   Neuroscience Research Focused on Neurodegenerative Diseases.....II-5
Neuroscience Research Advances to Make a Mark .....II-5
Summary of Major Neuroscience Research Developments in 2009.....II-5
1$100
   A. Alzheimer’s Market in Review.....II-6
The AD Epidemiology.....II-6
Table 2: World Alzheimer’s Disease Prevalence by Country/Region: Number of Patients in US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (Australia, India, Philippines and Rest of Asia-Pacific), Brazil and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: Alzheimer’s Disease Statistics in Top Seven Countries (US, Japan, Germany, France, UK, Italy and Spain): Number of Patients Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-7
The Impact of Dementia.....II-7
1$350
   A Look At AD Demographics.....II-8
A Global Overview.....II-8
1$100
   Geographic Overview.....II-9
Growth Drivers.....II-9
Aging Baby Boomers - The Market’s Growth Engine.....II-9
Table 4: AD Frequency Rates in the US and Europe: Percentage Share by Age Group (includes corresponding Graph/Chart).....II-9
1$350
   Unmet Medical Needs Drive Market Growth.....II-10
Growth Restrains.....II-10
Misdiagnosis.....II-10
Lack of Awareness.....II-10
High Cost of Treatment.....II-10
Market Outlook for Anti-AD Drugs.....II-10
1$100
   Cholinesterase Inhibitors – The Leader, but Not Strong Growth Contender.....II-11
NMDA Receptor Antagonists – Dynamic Growth Potential, Albeit A Small Base.....II-11
1$100
   Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in Select Countries.....II-12
Competitive Landscape.....II-12
1$100
   B. The Parkinson’s Market in Review.....II-13
The PD Epidemiology.....II-13
Table 5: World Parkinson’s Disease Prevalence by Country/Region: Number of Patients in the US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), China and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-13
1$350
   A Global Overview.....II-14
Dominance of Dopamine Agonists.....II-14
Stalevo Continues to Outshine.....II-14
The Slippery Path to Clinical Success.....II-14
Market Drivers.....II-14
Emergence of Dopamine Agonists as First Line Treatment.....II-14
1$100
   The Debut of Stalevo.....II-15
High Unmet Clinical Needs.....II-15
Market Inhibitors.....II-15
Lack of Awareness and Under-diagnosis.....II-15
Limitations of Existing Medicines.....II-15
1$100
   Restricted Period Use of Dopamine Agonists.....II-16
Generic Competition from L-Dopa and Carbidopa.....II-16
C. The Multiple Sclerosis Market in Review.....II-16
The MS Epidemiology.....II-16
1$100
   Table 6: World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-171$350
   Facts About Multiple Sclerosis.....II-18
Market Overview.....II-18
Interferon-based Drugs Lead Multiple Sclerosis Drugs Market.....II-18
1$100
   High Unmet Need and Rich Pipeline to Expand MS Market.....II-19
Sales Dip Inevitable for Current Therapies.....II-19
1$100
   Tough Times Ahead for Betaseron.....II-20
Competitive Landscape.....II-20
Table 7: Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart).....II-20
1$350
   D. The ALS Market in Review.....II-21
The ALS Epidemiology.....II-21
Market Overview.....II-21
1$100
   Sanofi-aventis – The ALS Drugs Market Leader.....II-22
E. The Huntington's Market in Review.....II-22
The HD Epidemiology.....II-22
1$100
   Market Outlook.....II-23
F. Neuropathic Pain Market in Review.....II-23
Market Overview.....II-23
1$100
   G. Prion Disease.....II-24
Disease Origin.....II-24
1$100
   Alzheimer’s Disease.....II-25
Select Pipeline Drugs for Alzheimer’s Disease.....II-25
Parkinson’s Disease.....II-25
1$100
   Select Pipeline Drugs for Parkinson’s Disease.....II-26
Huntington’s Disease.....II-26
Select Pipeline Drugs for Treatment of Huntington’s Disease.....II-26
1$100
   Multiple Sclerosis.....II-27
Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies.....II-27
1$100
   Select Pipeline Drugs for Multiple Sclerosis.....II-28
Amyotrophic Lateral Sclerosis.....II-28
Select Pipeline Drugs for Amyotrophic Lateral Sclerosis.....II-28
1$100
   Neurodegeneration.....II-29
An Overview of Factors that Link Neurodegenerative Diseases.....II-29
Genetics.....II-29
Intracellular Mechanisms.....II-29
Protein Degradation Pathways.....II-29
1$100
   Mitochondrial Dysfunction.....II-30
Axonal Transport.....II-30
Programmed Cell Death.....II-30
1$100
   An Overview of Select Major Neurodegenerative Diseases.....II-31
Alzheimer's Disease.....II-31
Definition.....II-31
Cause.....II-31
1$100
   Diagnoses.....II-32
Prevention.....II-32
Treatment.....II-32
1$100
   Anti-AD Drug Classes and Approved Products.....II-33
Parkinson’s Disease.....II-33
Definition.....II-33
Cause.....II-33
Diagnosis.....II-33
1$100
   Therapeutic Treatment.....II-34
List of Drugs Available for the Treatment of Parkinson’s Disease.....II-34
1$100
   Surgical Intervention.....II-35
Multiple Sclerosis.....II-35
Definition.....II-35
Types of Multiple Sclerosis.....II-35
1$100
   Table 8: Prevalence of Different Types of Multiple Sclerosis (includes corresponding Graph/Chart).....II-36
Etiology.....II-36
Pathology.....II-36
1$350
   Treatment.....II-37
List of Approved Multiple Sclerosis Drugs.....II-37
Huntington’s Disease.....II-37
Definition.....II-37
1$100
   Prognosis.....II-38
The Three Stages of HD.....II-38
1$100
   Symptoms and Signs.....II-39
List of Physical, Psychiatric and Cognitive Symptoms in Huntington’s
  Disease.....II-39
Diagnosis.....II-39
1$100
   Treatment.....II-40
Amyotrophic Lateral Sclerosis (ALS).....II-40
Definition.....II-40
Types of ALS.....II-40
1$100
   Familial ALS.....II-41
Sporadic ALS.....II-41
Guamanian ALS.....II-41
Etiology.....II-41
1$100
   Symptoms.....II-42
Diagnosis.....II-42
1$100
   Treatment.....II-431$100
   Neurodegenerative Drugs for Alzheimer’s Disease.....II-44
NMDA Receptor Antagonists (NMDARA).....II-44
Memantine.....II-44
1$100
   Cholinesterase Inhibitors (ChEIs).....II-45
Donepezil (Aricept).....II-45
Rivastigmine (Exelon).....II-45
Galantamine Hydrobromide (Razadyne).....II-45
1$100
   Tacrine (Cognex).....II-46
Other Alternatives.....II-46
Vitamin E.....II-46
Estrogen Therapy.....II-46
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).....II-46
Gingko Biloba.....II-46
Neurodegenerative Drugs for Parkinson’s Disease.....II-46
1$100
   Dopaminergic Agents.....II-47
Levodopa/Carbidopa.....II-47
Dopamine Agonists.....II-47
Bromocriptine/Parlodel.....II-47
1$100
   Ropinirole/Requip.....II-48
Pramipexole/Mirapex.....II-48
Cabergoline/Dostinex.....II-48
Apomorphine/Apokyn.....II-48
Other PD Drugs.....II-48
COMT Inhibitors.....II-48
1$100
   MAO-B Inhibitors.....II-49
Dopamine Amplifiers.....II-49
Anticholinergics.....II-49
Neurodegenerative Drugs for Huntington’s Disease.....II-49
1$100
   Tetrabenazine.....II-50
Others.....II-50
1$100
   Neurodegenerative Drugs for Multiple Sclerosis.....II-51
Interferon Drugs.....II-51
Beta Interferon Drugs for the Treatment of Multiple Sclerosis.....II-51
Non-Interferon Drugs.....II-51
1$100
   Non-Interferon Drugs for the Treatment of Multiple Sclerosis.....II-52
Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis.....II-52
Rilutek.....II-52
Symptomatic Treatment.....II-52
2$125
   Neurologix’s Non-dopamine Gene Therapy for PD.....II-54
Cell Cure’s Cell Replacement Therapy for PD.....II-54
Researches Developing Neuroprotective Agent for PD.....II-54
UT Southwestern Researchers Study New Compound for HD.....II-54
1$100
   UCLA Scientists Identify Molecular Switch Capable of Blocking HD.....II-55
Repligen Reports Detection of HDAC 3 Drug Target for Friedreich's Ataxia (US).....II-55
Tel Aviv University Reports Stem Cell Cure for Neurodegeneration (Israel).....II-55
1$100
   Cambridge Researchers Develop Novel Drug Targets for HD.....II-56
Emory Research Team Develops First Transgenic Monkey Model of HD.....II-56
1$100
   KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD Mutation.....II-57
Researchers Identify New Gene for ALS.....II-57
Q Therapeutics and Johns Hopkins Research Team to Study GRPs in ALS Model.....II-57
ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS Treatment.....II-57
1$100
   Allen Institute and ALS TDI to Conduct ALS Study.....II-58
Life Technologies to Develop Neurodegenerative Disease Models.....II-58
Neuralstem and University of Michigan Collaborate for ALS Research.....II-58
1$100
   ALS TDI and MDA Collaborate for ALS Drug Discovery.....II-591$100
   Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA.....II-60
Medivation's Dimebon Fails to Meet End Points in Phase III Trial.....II-60
QR Pharma Annuls Phenserine Production.....II-60
1$100
   Neurologix Begins Phase II Studies for Parkinson's Disease Treatment (US).....II-61
Biovail and ACADIA Complete Phase II Clinical Trials for Pimavanserin (Canada,
  US).....II-61
Merck Serono Announces Encouraging Phase III Results of Oral Mylinax.....II-61
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT.....II-61
1$100
   NeuroSearch Presents ACR16 as Novel Huntington’s Disease Therapy.....II-621$100
   Eli Lilly Launches Two Phase-III Trials for Solanezumab(i) Worldwide (US).....II-63
Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod.....II-63
1$100
   CytRx Initiates Phase II/III Clinical Trial for Arimoclomol.....II-64
Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120 (Switzerland).....II-64
H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark).....II-64
Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2-73 Phase-I Clinical Tests
  (Switzerland).....II-64
Bayer Schering Pharma Completes Stage-II Trials for BAY 94-9172 (Germany).....II-64
1$100
   Newron and Merck Serono Start Second Round of Phase III Tests for Safinamide
  (Italy).....II-65
Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon
  Beta-1a.....II-65
ExonHit Therapeutics Completes Phase-II Clinical Study for EHT 0202 (France).....II-65
Kyowa Hakko Kirin to Start Phase-III Clinical Trials for Istradefylline in
  Japan.....II-65
Medtronic and Alnylam Pharma Report Pre- Clinical Results of ALN-HTT (US).....II-65
1$100
   Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Treatment.....II-66
NeuroSearch Begins Critical Phase III Program with ACR16.....II-66
Avicena to Proceeds with Phase III Trial of HD-02.....II-66
1$100
   Knopp Neurosciences Commences Phase II Study of KNS- 760704.....II-67
Maas Biolab SBIR Initiates Phase II for Cyclosporin.....II-67
MediciNova Announces Phase II Clinical Trial Results of MN-166.....II-67
1$100
   Avicena Proceeds to NIH Sponsored Phase III Trial for D-02.....II-68
EnVivo Pharmaceuticals Progresses on Major HDACi Program.....II-68
NeuroSearch Files CTA in Europe to Begin Clinical Phase III Program with ACR16.....II-68
2$125
   Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple
  Sclerosis.....II-70
Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA.....II-70
Accera Introduces Axona™.....II-70
Eisai Receives Approval for Aricept®.....II-70
1$100
   Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of
  MS.....II-71
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of
  MS.....II-71
Novartis Obtains FDA Approval for Extavia.....II-71
ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US).....II-71
1$100
   Knopp’s KNS-760704 Receives EC Orphan Designation.....II-72
NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (Europe).....II-72
Cambridge Labs Receives Spanish Marketing Approval for Tetrabenazine.....II-72
1$100
   ArmaGen Technologies Secures Orphan Drug Designation for AGT-181 from FDA (US).....II-73
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for Cysteamine.....II-73
Elan and Biogen Receive Health Canada Approval for MS Use of Tysabri™.....II-73
Exelon Patch Wins EU Approval for Alzheimer's Treatment.....II-73
1$100
   Isis Pharma Receives Orphan Drug Designation for ISIS333611.....II-741$100
   Lundbeck Acquires LifeHealth.....II-75
StemCells Acquires Stem Cell Sciences.....II-75
Oryzon Takes Over Crystax Pharmaceuticals.....II-75
1$100
   JANSSEN Acquires Elan’s Alzheimer’s Immunotherapy Program.....II-76
Hisamitsu Takes Over Noven Pharmaceuticals.....II-76
Lundbeck Takes Over Ovation Pharmaceuticals.....II-76
1$100
   Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences.....II-77
Genzyme Acquires Assets of Targeted Genetics Corporation.....II-77
Merck Takes Over Insmed’s Follow-on Biologics Assets.....II-77
NeuroSearch Reacquires Global Rights to ACR16.....II-77
1$100
   Biovail Acquires Worldwide Rights to Tetrabenazine.....II-78
Raptor Pharmaceuticals Merges with TorreyPines.....II-78
iZumi Bio Merges with Pierian; Forms iPierian, Inc......II-78
1$100
   Cell Genesys Merges with BioSante Pharmaceuticals.....II-79
CeNeRx BioPharma Secures Marketing and Development Rights for CXB909.....II-79
Laureate Pharma and ZZ Biotech Ink Agreement.....II-79
QxPharma Limited Signs Agreement with Patheon.....II-79
Cambridge Labs Signs New Agreements to Market Xenazine® in North America.....II-79
1$100
   Shire and UCB Ink Agreement.....II-80
NeuroNova and Genentech Signs Agreement for VEGF Use in ALS Treatment.....II-80
1$100
   Biovail to Acquire North American Rights to Fipamezole from Santhera.....II-81
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane.....II-81
KineMed Collaborates with Bristol-Myers Squibb.....II-81
Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim.....II-81
1$100
   Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™.....II-82
Genzyme Corp. and Bayer HealthCare Sign Agreement.....II-82
CHDI Foundation Inks Agreement with AMRI for Drug Discovery.....II-82
1$100
   Addex Pharmaceuticals Inks Licensing Agreement with Merck.....II-83
Acccera Sets Up Neuera Pharmaceuticals.....II-83
Evotec Inks Research Agreement with Biogen Idec.....II-83
1$100
   ALS TDI and Asklepios to Develop ALS Therapy Delivery Alternatives.....II-84
Evotec Extends Collaboration with Boehringer Ingelheim.....II-84
Neuralstem Collaborates to Develop Neural Stem Cell Therapies.....II-84
Eisai and Pfizer Ink Agreement.....II-84
1$100
   BioAdvance Invests in TREVENTIS Corp......II-85
AstraZeneca Announces Milestone Payments to Targacept for AZD3480 Program.....II-85
Suven Life Sciences Secures Two Patents in the US.....II-85
Eisai Terminates Contract with Nitto Denko Corporation.....II-85
MJFF Awards Grants to Targacept.....II-85
1$100
   Metabolic Solutions Receives Grant from Alzheimer's Drug Discovery Foundation.....II-86
Medical Research Council and Wellcome Trust to Fund Neurodegeneration Research.....II-86
Biovail Acquires Prestwick Pharmaceuticals.....II-86
1$100
   GlaxoSmithKline Acquires Sirtris Pharmaceuticals.....II-87
Newron Pharmaceuticals Acquires Hunter-Fleming.....II-87
SYGNIS Pharma Purchases Amnestix.....II-87
1$100
   Proximagen Neuroscience Acquires Cambridge Biotechnology.....II-88
Teva Acquires Barr Pharmaceuticals.....II-88
Eisai Acquires MGI Pharma.....II-88
Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US.....II-88
Targeted Genetics Acquires Rights to the siRNA Development Program.....II-88
1$100
   Insmed Obtains Royalty-Free Global Rights for IPLEX™.....II-89
Pfizer and Serenex Ink Agreement.....II-89
Dr. Reddy's Laboratories Inks Agreement with Sygnis Pharma.....II-89
1$100
   Cambridge Labs Inks and Renews Agreements in Multiple Nations.....II-90
CHDI Inked Collaboration Agreements with Galapagos.....II-90
Power3 Medical Products and StemTroniX Sign Letter of Intent.....II-90
ALS Therapy Development Institute and Allen Institute Ink Agreement.....II-90
1$100
   Yissum Inks Licensing Agreement with Eucalyptus.....II-91
GlaxoSmithKline Biologicals Enters into Licensing Agreement with AFFiRiS.....II-91
Neurologix and Aegera Therapeutics Ink Licensing Agreement.....II-91
1$100
   Neurobiological Inks Licensing Agreement with BIAR.....II-92
Raptor Pharma Forms Collaboration with CHU d'Angers for Phase II Trial.....II-92
Amorfix Completes Research Partnership with Biogen Idec.....II-92
1$100
   Apitope Raises Financing for Developing Multiple Sclerosis Compound.....II-93
Pipex Pharmaceuticals Changes Corporate Name to Adeona Pharmaceuticals.....II-93
MethylGene Terminates Collaboration Agreement with EnVivo Pharmaceuticals.....II-93
Varinel Receives Fund from Alzheimer's Drug Discovery Foundation.....II-93
1$100
   PharmatrophiX Receives Grants from Alzheimer's Drug Discovery Foundation.....II-94
Eisai Acquires Morphotek.....II-94
Transition Therapeutics Acquires NeuroMedix.....II-94
Merz Licenses Anti-Alzheimer’s Drug Technology from TAU.....II-94
Intellect Neurosciences Inks Agreement with CHDI Foundation to Evaluate Potential of
  OXIGON™.....II-94
1$100
   Intellect Signs Licensing Agreement with Immuno- Biological Laboratories.....II-95
Boehringer Ingelheim Signs R&D Agreement with Ablynx.....II-95
Evotec Teams Up with Boehringer Ingelheim.....II-95
Siemens Medical Signs Partnership Agreement with Wyeth.....II-95
1$100
   Pipex Pharma Signs Agreement for Evaluation of COPREXA.....II-96
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker.....II-96
Pfizer Joins Forces with Genizon for AD.....II-96
Avicena Teams Up with NINDS for Phase III Trial of PD-02.....II-96
QSV and Artielle Sign Contract to Produce RTL-1000 (To be added to Canada).....II-96
1$100
   ALS TDI Selects Microbix to Manufacture Adenoviruses.....II-97
Maas BiolAB Receives SBIR Grant for ALS Study.....II-97
1$100
   Amarin Corporation PLC (Ireland).....II-98
AstraZeneca PLC (UK).....II-98
Avanir Pharmaceuticals, Inc. (US).....II-98
Avigen, Inc. (US).....II-98
1$100
   Bayer Schering Pharma AG (Germany).....II-99
Boehringer Ingelheim GmbH (Germany).....II-99
1$100
   Biogen Idec Inc. (US).....II-100
Bristol-Myers Squibb Co. (USA).....II-100
1$100
   Biovail Corporation (Canada).....II-101
Ceregene, Inc. (US).....II-101
Eisai, Inc. (USA).....II-101
1$100
   Elan Pharmaceuticals (US).....II-102
Eli Lilly and Company (USA).....II-102
1$100
   Forest Laboratories, Inc. (US).....II-103
GlaxoSmithKline PLC (UK).....II-103
1$100
   H. Lundbeck A/S (Denmark).....II-104
Merz Pharmaceuticals GMBH (Germany).....II-104
Merck Serono SA (Switzerland).....II-104
1$100
   Mitsubishi Tanabe Pharma Corporation (Japan).....II-105
Neurologix, Inc. (US).....II-105
1$100
   NeuroSearch A/S (Denmark).....II-106
Novartis AG (Switzerland).....II-106
1$100
   Pfizer, Inc. (US).....II-107
Sanofi-aventis S.A (France).....II-107
1$100
   Shire Pharmaceuticals Group PLC (UK).....II-108
Teva Pharmaceutical Industries Limited (Israel).....II-108
1$100
   Valeant Pharmaceuticals International (US).....II-109
Wyeth Pharmaceuticals, Inc. (US).....II-109
1$100
   Analytics by Geographic Region.....II-110
Table 9: World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-110
1$350
   Table 10: World 10-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-1111$350
   Analytics by Disease Type.....II-112
Table 11: World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Disease Type - Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-112
1$350
   Table 12: World 10-Year Perspective for Neurodegenerative Drugs by Disease Type - Percentage Breakdown of Dollar Sales for Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-1131$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
AD Market Overview.....III-1
Approval of Cholinesterase Inhibitors for MCI to Drive Market.....III-1
1$75
   Status of AD Drugs.....III-2
Prevalence.....III-2
Table 13: US Prevalence of Alzheimer’s Disease for 2005-2010 (includes corresponding Graph/Chart).....III-2
1$200
   PD Market Overview.....III-3
Levodopa/Carbidopa on Declining Spree.....III-3
Patent Expiry Status.....III-3
Patent Expiry Status of Parkinson’s Disease Drugs in the US.....III-3
Prevalence.....III-3
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market.....III-3
Clinical Trials.....III-3
2$100
   Product Launches.....III-51$75
   Strategic Corporate Developments.....III-610$275
   Key Players.....III-164$150
   B. Market Analytics.....III-20
Table 14: US Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-20
1$200
   A. Market Analysis.....III-21
Current & Future Analysis.....III-21
Table 15: Prevalence of Dementia in Europe by Select Countries: 2005 (includes corresponding Graph/Chart).....III-21
1$200
   Alzheimer’s and Parkinson’s Prevalence in Europe.....III-22
Table 16: European Alzheimer’s Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-22
1$200
   Table 17: European Parkinson’s Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-231$200
   Table 18: Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-241$200
   Low Penetration to Fuel Growth in European MS DMDs Market.....III-25
Stroke Prevalence in Europe – A Perspective Builder.....III-25
Table 19: Stroke Prevalence Rates in European Males (2004): Breakdown by Country and Age Group (Per 100 000 People).....III-25
1$200
   Table 20: Stroke Prevalence Rates in European Females (2004): Breakdown by Country and Age Group (Per 100 000 People).....III-26
Clinical Trials.....III-26
2$200
   Product Launches/Approvals.....III-28
Strategic Corporate Developments.....III-28
4$150
   Key Players.....III-324$150
   B. Market Analytics.....III-36
Table 21: European Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Country/ Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-36
1$200
   Table 22: European 10-Year Perspective for Neurodegenerative Drugs by Country/Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart).....III-371$200
   A. Market Analysis.....III-38
Current & Future Analysis.....III-38
Canada – High Prevalence Rates for Multiple Sclerosis.....III-38
Table 23: Multiple Sclerosis Prevalence in Canada For Years 2001 through 2010 (includes corresponding Graph/Chart).....III-38
1$200
   Incidence of Multiple Sclerosis on the Rise in India.....III-39
Table 24: Multiple Sclerosis Prevalence in India for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-39
1$200
   Alzheimer’s and Parkinson’s Prevalence in Canada.....III-40
Table 25: Alzheimer’s and Parkinson’s Diseases and Multiple Sclerosis Prevalence in Canada for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Alzheimer’s and Parkinson’s Prevalence in Japan.....III-41
Table 26: Alzheimer’s and Parkinson’s Diseases Prevalence in Japan for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-41
1$200
   Alzheimer’s Prevalence in Asia-Pacific.....III-42
Table 27: Alzheimer’s Disease Prevalence in Asia-Pacific by Country: Number of Patients for Australia, India, Philippines and Rest of Asia-Pacific in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart).....III-42
Clinical Trials.....III-42
1$200
   Research Studies/Other Developments.....III-43
Product Launches/Approvals.....III-43
Strategic Corporate Developments.....III-43
2$100
   Select Players.....III-452$100
   B. Market Analytics.....III-47
Table 28: Rest of World Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market - Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-47
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com